The enterohepatic circulation is essential for the maintenance of bile acids and cholesterol homeostasis. The ileal bile acid transporter on the apical membrane of enterocytes mediates the intestinal uptake of bile salts, but little is known about the bile salt secretion from the basolateral membrane of enterocytes into blood. In the basolateral membrane of enterocytes, an ATP-binding cassette transporter, multidrug resistance protein 3 (MRP3), is expressed, which has the ability to transport bile salts. We hypothesized that MRP3 might play a role in the enterohepatic circulation of bile salts by transporting them from enterocytes into circulating blood through the up-regulation of MRP3 expression, so we investigated the transcriptional control of MRP3 in response to bile salts. MRP3 mRNA levels were increased about 3-fold in human colon cells by chenodeoxycholic acid (CDCA), in a dose-and time-dependent manner. In the promoter assay, the promoter activity of MRP3 was increased about 3-fold over the basal promoter activity when treated with CDCA, and the putative bile salt-responsive elements exist in the region ؊229/؊138 including two ␣-1 fetoprotein transcription factor (FTF)-like elements. Constructs with a specific mutation in the consensus sequence of FTF elements showed no increase in basal transcriptional activity following CDCA treatment. In electrophoretic mobility shift assay with nuclear extracts, specific binding of FTF to FTF-like elements was observed when treated with CDCA. The expression of FTF mRNA levels were also markedly enhanced in response to CDCA, and overexpression of FTF specifically activated the MRP3 promoter activity about 4-fold over the basal promoter activity. FTF thus might play a key role not only in the bile salt synthetic pathway in hepatocytes but also in the bile salt excretion pathway in enterocytes through the regulation of MRP3 expression. MRP3 may contribute as a plausible bile salt-exporting transporter to the enterohepatic circulation of bile salts.
The enterohepatic circulation is essential for the maintenance of bile acids and cholesterol homeostasis. The ileal bile acid transporter on the apical membrane of enterocytes mediates the intestinal uptake of bile salts, but little is known about the bile salt secretion from the basolateral membrane of enterocytes into blood. In the basolateral membrane of enterocytes, an ATP-binding cassette transporter, multidrug resistance protein 3 (MRP3), is expressed, which has the ability to transport bile salts. We hypothesized that MRP3 might play a role in the enterohepatic circulation of bile salts by transporting them from enterocytes into circulating blood through the up-regulation of MRP3 expression, so we investigated the transcriptional control of MRP3 in response to bile salts. MRP3 mRNA levels were increased about 3-fold in human colon cells by chenodeoxycholic acid (CDCA), in a dose-and time-dependent manner. In the promoter assay, the promoter activity of MRP3 was increased about 3-fold over the basal promoter activity when treated with CDCA, and the putative bile salt-responsive elements exist in the region ؊229/؊138 including two ␣-1 fetoprotein transcription factor (FTF)-like elements. Constructs with a specific mutation in the consensus sequence of FTF elements showed no increase in basal transcriptional activity following CDCA treatment. In electrophoretic mobility shift assay with nuclear extracts, specific binding of FTF to FTF-like elements was observed when treated with CDCA. The expression of FTF mRNA levels were also markedly enhanced in response to CDCA, and overexpression of FTF specifically activated the MRP3 promoter activity about 4-fold over the basal promoter activity. FTF thus might play a key role not only in the bile salt synthetic pathway in hepatocytes but also in the bile salt excretion pathway in enterocytes through the regulation of MRP3 expression. MRP3 may contribute as a plausible bile salt-exporting transporter to the enterohepatic circulation of bile salts.
Bile salts are synthesized from cholesterol in the hepatocytes, excreted into the bile duct (1) , and finally excreted into the gut, and more than 90% of bile salts are reabsorbed throughout enterocytes and return, via the portal blood, to the liver. This enterohepatic circulation is essential for the maintenance of bile salts and cholesterol homeostasis (2) .
Recent studies have described how bile salts/cholesterol homeostasis regulatory mechanisms are controlled through enterohepatic circulation at molecular levels (3) (4) (5) (6) . In the synthetic pathway in the liver, bile salts exert negative feedback regulation on their own synthesis from cholesterol. CYP7A1, 1 which is the first and rate-limiting enzyme in a major bile salt synthetic pathway, is under transcriptional control through a specific bile salt nuclear receptor, farnesoid X receptor (FXR) (7, 8) . Transcription of the CYP7A1 gene is turned down by bile acids through the interaction of an orphan nuclear receptor FTF with the supressor small heterodimer partner, which is up-regulated by binding of FXR to bile acids (7) (8) (9) (10) .
In view of the excretion/efflux pathway of bile salts, several transporters that are expressed in the liver and/or gut confer enterohepatic circulation by exporting bile salts. In the liver, intracellular bile salts are uptaken from circulating blood through the basolateral membrane transporter, NTCP, and they are excreted into the bile duct mainly by BSEP in the canalicular membrane of the hepatocytes (1). MRP2, a member of the MRP superfamily, expressed in the canalicular membrane of hepatocytes, may also export bile salts into the bile duct (11) . In the gut, bile salts enter the enterocytes through the ileal apical membrane sodium-dependent bile acid transporter and interact with FXR, resulting in up-regulation of the gene encoding cytosolic ileal bile acid-binding protein, which facilitates intracellular transport of bile salts and protects enterocytes from the detergent effects of bile salts (7, 12, 13) . However, little is known about how bile salts are secreted from basolateral membrane into blood (14 -16) .
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MRP3 (22, 23) , have been functionally characterized as conjugate export pumps. MRP2 is predominantly expressed in the canalicular membrane of hepatocytes (18, 21, 24) . In contrast, MRP1 and MRP3 are expressed in the basolateral membrane of hepatocytes and enterocytes (19, (25) (26) (27) . In rats receiving common bile duct ligation, estrogen treatment, and administration of endotoxin as acquired cholestasis models, basolateral Ntcp was down-regulated by transcriptional mechanisms, and also canalicular Bsep was initially diminished but partially recovered as common bile duct ligation continues (28, 29) . The expression of Mrp2 is down-regulated in these animal models of cholestasis through both transcriptional and post-transcriptional events (30) , and the expression of Mrp3 was induced (31, 32) . In humans, Dubin-Johnson syndrome, an autosomal recessive disease, is characterized by a defect in the transfer of endogenous and exogenous anionic conjugates from hepatocytes into the bile because of mutations in MRP2 gene (33) (34) (35) (36) . It was reported that MRP3 was up-regulated in a patient with Dubin-Johnson syndrome (27) . MRP3 thus appears to compensate for the impaired function of MRP2 in the liver and respond to bile salts at transcriptional levels. These experiments suggest that bile salt transporters in hepatocytes respond to cholestasis in a direction that tends to diminish retention of bile salts in the liver, resulting in protection of the tissue from further injury (30) .
Relevant studies demonstrated that MRP3 transports the bile salts, 17␤-estradiol, and some anti-cancer drugs (23, 37) . While the expression of MRP1 and MDR1 is high in hepatocytes, expression of both MRP1 and MDR1 as well as BSEP is very low or absent in enterocytes. By contrast, expression of MRP3 appears in the basolateral enterocyte membrane of humans and rats, suggesting that MRP3 might be responsible for the intestinal transport of organic anions (18, 27, 31) . Since MRP3, which transports bile salts, is localized in the basolateral membrane of enterocytes, MRP3 may play a role in the enterohepatic circulation of bile salts by transporting them from enterocytes into circulating blood to prevent the accumulation of intracellular bile salts. Furthermore, since expression of apical bile salt transporter is induced by bile salts (38), we hypothesize that MRP3 expression could be up-regulated in a coordinated fashion in response to bile salts in the enterocytes. In this study, MRP3 mRNA was found to be up-regulated in response to bile salts in enterocytes, and we examined whether bile salts affect transcriptional control of MRP3 gene in enterocytes. We observed that FTF-like elements are responsible for the up-regulation of MRP3 gene in response to bile salts. We would propose a novel idea that MRP3 may play a role in bile salts homeostasis through enterohepatic circulation at transcriptional levels.
EXPERIMENTAL PROCEDURES
Cell Culture-As an in vitro model, we used Caco2 cells from a human colon adenocarcinoma cell line, which retain many of the characteristics of normal enterocytes (39, 40) . Cells were cultured in Dulbecco's modified Eagle's medium (Nissui Seiyaku, Tokyo, Japan) supplemented with 10% fetal calf serum, 0.1 mM nonessential amino acids (Invitrogen, Paisley, UK) in a humidified incubator (5% CO 2 , 37°C). The medium contained 0.292 mg/ml glutamine, 100 mg/ml kanamycin, and 100 units/ml penicillin (41) .
Chemicals and Experimental Treatments-CDCA, TCDCA, taurocholic acid, taurolithocholic acid, and ursodeoxycholic acid were purchased from Sigma. To study the effect of bile salts treatment on intestinal MRP3 mRNA expression in vitro, cells were cultured for 48 h with 0 -100 M CDCA, TCDCA, taurocholic acid, taurolithocholic acid, or ursodeoxycholic acid and were treated with 100 M CDCA for 0 -48 h. For the preparation of nuclear extracts, cells were treated with 100 M CDCA for 12 h.
RNA Isolation and Northern Blot Analysis-Total RNA was isolated using an Rneasy spin column (Quiagen, Hilden, Germany). RNA samples (15 g/lane) were separated on a 1% formaldehyde-agarose gel and were transferred to a membrane as described by Tanaka et al. (41) . The membranes were prehybridized and hybridized with ␣-32 P-labeled probes (41) . An MRP3 cDNA probe (285 bp) was produced by PCR using the primer pair 5Ј-GTCTTTGTTCCAGACGCAGTC-3Ј and 5Ј-GGAGA-TGAAGAACAGGCAGG-3Ј. A FTF cDNA probe (1109 bp) was digested from the pCI-FTF vector by BamHI. Radioactivity was visualized by autoradiography and was analyzed using a Fujix Bas 2000 bioimaging analyzer (Fuji Photo Film Co., Tokyo, Japan).
Isolation, Cloning, and Sequencing of the 5Ј-Flanking Region of the Human MRP3 Gene-A human placental genomic library in EMBL3 was screened with a fragment of the 5Ј-untranslated region of MRP3 cDNA obtained by the 5Ј-rapid amplification of cDNA ends method. Several restriction fragments were subcloned into the pUC18 plasmid. Chain elongation and termination were performed using a BigDye Terminator Cycle Sequencing kit (Applied Biosystems, Tokyo, Japan), and the nucleotides were sequenced using a DNA-sequencing system (model 377; Applied Biosystems). Data were analyzed using GeneWorks software (IntelliGenetics, Mountain View, CA).
Reporter Gene Constructs-To functionally characterize the 5Ј-flank- ing region of the human MRP3 gene, a series of 5Ј deletions ranging from Ϫ1958 to Ϫ13 bp of the upstream sequence from the ATG codon were amplified using PCR from the subcloned pUC18 plasmid with KOD Dash polymerase (TOYOBO, Tokyo, Japan). The upstream primers contained a 5Ј-flanking SacI restriction site, whereas the downstream primers were flanked by the HindIII site. The PCR product was cloned into pGEM-Teasy vector (Promega, Madison, WI), which was subsequently digested with SacI and HindIII. The fragments of the 5Ј region of the MRP3 gene were ligated into the SacI and HindIII sites of pGL3-basic vector (Promega). All plasmids were analyzed by restriction digestion, and the promoter inserts were sequenced. Site-directed mutagenesis of the FTF in p-520 MRP3 Luci was performed by a PCRbased method. Two FTF-like elements exist in p-520 MRP3 Luci; we named the upper region site 1 and the lower region site 2. The promoter sequences were amplified first with Taq polymerase, a 5Ј-primer (GA-GCTCAGCTTCCTGATTGAGC), and a 3Ј-primer that introduces a specific mutation into the FTF site 1 region (CGCCGTGCTACATGCC-CCCCCAC) or into the FTF site 2 region (ACCTCTGCCCTACATTCC-CTCCCA), and another pair, a 5Ј-primer that introduces specific mutation into the FTF site 1 region (GTGGGGGGGCATGTAGCACGGCG) or into the FTF site 2 region (TGGGAGGGAATGTAGGGCAGAGGT) and a 3Ј-primer (ACCGCGCTCGCCTTCCTTGC). A second PCR was then performed with Taq polymerase using the first PCR products as a template. The PCR product was cloned into pGEM-Teasy vector, which was subsequently digested with SacI and HindIII. The fragments were ligated into the SacI and HindIII sites of pGL3-basic vector (Promega).
Luciferase Assay-Cells were transiently transfected by the LipofectAMINE method. Briefly, a mixture of 50 g of LipofectAMINE 2000 reagent (Invitrogen, Paisley, UK) and 1 g of reporter plasmid was transfected into the cells and kept there for 6 h, and then fresh medium was added. The 100 ng of pRL-CMV (Promega) plasmid containing Renilla luciferase driven by the CMV promoter was co-transfected as a transfection control. The pGL3-control vector (Promega) containing SV40 promoter-enhancer and promoterless pGL3-basic vector were transfected as positive and negative controls of promoter activity, respectively. The 200 ng of pCI-FTF was transfected into COS7 cells with 1 g of reporter plasmid and 100 ng of pRL-CMV. Luciferase activities were measured using the Dual Luciferase assay system (Promega). Promoter activities are given as mean Ϯ S.D. of triplicate transfections. The level of significance of promoter activities in the presence of regular substrates was determined using Student's t test.
EMSA-Nuclear extracts (6 g of protein) were prepared as described (42) previously, and they were incubated for 30 min at room temperature in a final volume of 20 l of reaction mixture containing 20 mM Tris-HCl (pH 8.0), 50 mM KCl, 0.2 mM EDTA, 10% (v/v) glycerol, 10 ng of poly(dI-dC), and 1 ϫ 10 4 cpm of 32 P-labeled oligonucleotide probe in the absence or presence of various competitors. Next, the samples were electrophoresed on 5% polyacrylamide gel (polyacrylamide/bisacrylamide ratio, 79:1) in a Tris borate buffer. The gel was exposed to an imaging plate and analyzed using a Fujix BAS 2000 bioimage analyzer (Fuji Photo Film Co.). The DNA sequence of the sense strand of each oligonucleotide is listed in Fig. 6A . For supershift experiments, 1 l of the crude serum was used.
RESULTS

Bile Salts Increase the Expression of the Human MRP3
mRNA-To examine whether the expression of ABC transporters appearing in enterocytes is altered by bile salts, we performed Northern blot analysis by using Caco2 cells. Treatment with 100 M concentrations of several series of bile salts, CDCA, TCDCA, taurocholic acid, and taurolithocholic acid, for 48 h increased MRP3 mRNA levels about 3-5-fold in Caco2 cells, while ursodeoxycholic acid treatment did not enhance MRP3 mRNA expression (Fig. 1A) .
We next examined dose response to bile salt and time kinetics for up-regulation of the MRP3 gene by CDCA. Treatment with CDCA for 48 h increased mRNA levels of MRP3 about 2-5-fold in a dose-dependent manner, with a maximum increase observed at 10 -100 M (Fig. 1B) . By contrast, there was no increase of mRNA levels of the ABC transporters MDR1 and MRP2, which are expressed on the apical membrane of entero- cytes by CDCA treatment (Fig. 1B) . In the time kinetic analysis with CDCA treatment, MRP3 mRNA levels were increased 2-4-fold when treated for more than 6 h with 100 M CDCA, and maximal increase was observed at 12 h (Fig. 1C) .
The Human MRP3 Gene Promoter Activity Is Up-regulated by CDCA-We determined by nuclear run-on assay that the up-regulation of MRP3 gene by CDCA was due to transcriptional control and observed enhanced transcription activity of MRP3 in the nuclear run-on assay when treated with bile salt (data not shown). We then cloned the MRP3 promoter region up to Ϫ1.9 kilobases from the ATG codon, and a series of promoter deletions were constructed in the reporter gene vector pGL3 basic vector (Fig. 2) . By making a computer-aided analysis with the TFMATRIX transcription factor binding site profile data base, we identified several consensus motifs for transcription factor binding sites (Fig. 2) . The luciferase activity by a series of 5Ј-deleted promoter constructs after 48 h of transfection without CDCA treatment (Fig. 2) . Compared with p-311, the luciferase activity decreased to 50% when p-229 was assayed, suggesting that a putative positive cis-element was located in the Ϫ311/Ϫ229 region. Furthermore, we observed more than a 50% decrease in the luciferase activity by p-138 compared with p-311. These results suggest that a positive regulatory element is localized in the Ϫ311/Ϫ138 region in transfected cells. We next investigated which region of MRP3 promoter was responsible for CDCA-induced activation. The luciferase activity of p-520, p-311, and p-229 was about 2-4-fold increased compared with the luciferase activity of untreated control when treated with 100 M CDCA for 24 h. By contrast, the luciferase activity of p-138 was not increased by CDCA (Fig. 3) . These results suggest that an element responsible for MRP3 promoter activation by CDCA is located between Ϫ229 and Ϫ138. This region contains two putative FTF binding elements (Ϫ222/Ϫ218 and Ϫ199/Ϫ195).
Mutation Analysis of MRP3 Promoter Activity-To examine whether mutations of the binding sites for FTF could affect the up-regulation of MRP3 promoter activity in response to CDCA, we made the constructs containing the promoter sequence with a specific mutation in each consensus sequence or both consensus sequences of two FTF binding elements, named p-520mut1, p-520mut2, and p-520mut3 (Fig. 4A) . Introduction of the specific mutation into either FTF1 or FTF2 and into both FTF1 and FTF2 completely inhibited CDCA-induced luciferase activity, suggesting that both of the two FTF-like elements have a regulatory role in the alteration of MRP3 expression in response to CDCA. The p-520mut1, p-520mut2, and p-520mut3 constructs showed no apparent change of the basal transcriptional activity in the absence of CDCA treatment, suggesting that these mutations did not affect the basal MRP3 promoter activity (Fig. 4B) .
FTF Has Binding Activity with MRP3 Promoter and a Regulatory Role in the MRP3 Expression in
Response to CDCA-To investigate whether MRP3 transcription activated by CDCA was altered by the interplay of FTF, we performed EMSA to study interaction of MRP3 promoter with FTF sequence by using nuclear extracts of Caco2 cells after CDCA treatment for 12 h. The DNA sequence of the sense strand of oligonucleotide, FTF, is listed in Fig. 5A . We also made three types of mutant oligonucleotides containing the internal mutations of FTF binding elements of oligonucleotides FTF1, FTF2, and FTF3 (Mut-FTF1, Mut-FTF2, and Mut-FTF3, respectively). In addition, we made Mut-FTF4, oligonucleotides containing the internal mutations between the two FTF binding elements (Fig.  5A) . EMSA was performed using the radiolabeled FTF as a probe. The retarded band (a) was observed when the probe FTF interacted with nuclear extracts of CDCA-treated cells (Fig.  5B) . The specificity of the DNA-protein interaction was demonstrated by appropriate competition assays. The upper retarded band (a) was almost completely obscured by a 20-fold excess of the unlabeled oligonucleotides FTF, FTF1, and FTF2 (Fig. 5B) . The exogenous addition of excess amounts of mutant oligonucleotides Mut-FTF1 and Mut-FTF2, containing mutations of one of the FTF binding elements, and Mut-FTF4, containing the internal mutations between the two FTF binding elements, could also inhibit the protein binding to the probe FTF (Fig. 5B) . By contrast, Mut-FTF3, oligonucleotides containing mutations in both of the two FTF binding elements, did not obscure the retarded band (a) (Fig. 5B) .
To examine whether the nuclear factor interacting with the FTF element on MRP3 promoter is FTF, we used a specific antibody developed against the FTF. Nuclear extract was preincubated with antibodies raised against a peptide corresponding to the DNA binding domain of FTF, and the retarded band was abolished (Fig. 6 ), but preimmune serum did not affect the retarded band. The protein that bound to the probe FTF appears to be FTF.
Up-regulation of FTF mRNA by CDCA and Activation of MRP3 Promoter by Overexpression of FTF-We examined whether the expression of the FTF gene was affected by CDCA. In Northern blot analysis by using Caco2 cells treated with or without 100 M of CDCA for 48 h, we observed that human FTF mRNA levels were markedly increased by treatment with CDCA (Fig. 7) . We next confirmed if FTF could directly modulate MRP3 promoter activity when FTF was overexpressed in COS7 cells (Fig. 8) . The luciferase activity of p-520 was about 3-fold increased when 200 ng of pCI-FTF was co-transfected. By contrast, introduction of the specific mutation into either FTF1 or FTF2 and into both FTF1 and FTF2 completely inhibited FTF-induced luciferase activity.
DISCUSSION
In our present study, we observed that the cellular mRNA levels of MRP3 were increased about 3-fold in human colon cells by various bile salts such as CDCA, TCDCA, and taurocholic acid, while the expression of the other ABC transporters MDR1 and MRP2 in apical enterocyte membrane was not enhanced (Fig. 1) . These findings suggest that a basolateral export system via MRP3 may secrete bile salts into portal blood FIG. 5 . A, sequences of oligonucleotides used for EMSA. EMSA was performed using the radiolabeled probe, including both of two FTF binding elements (Ϫ226/ Ϫ185). For the competition assay, the unradiolabeled probe (FTF), oligonucleotides containing one of two FTF binding elements (Ϫ231/Ϫ203 (FTF1) or Ϫ208/ Ϫ181 (FTF2)), oligonucleotides containing internal mutations of FTF binding elements (Mut-FTF1, Mut-FTF2, and Mut-FTF3), and oligonucleotides containing internal mutations between two FTF binding elements (Mut-FTF4) were used as the competitors. Lowercase characters delineate mutated bases. B, effect of CDCA on nuclear factor binding to the FTF-like element on the MRP3 promoter. Cells were incubated with 100 M CDCA for 12 h. The cells were harvested, nuclear extracts were prepared, and the extracts (6 g of protein) incubated with 32 P-labeled oligonucleotide were resolved by gel electrophoresis. A 20-fold excess of the unlabeled oligonucleotide was added for the competition. The bar (a) indicates the retarded DNA-protein complex. and protect enterocytes from further intracellular accumulation of bile salts. However, it remains to be determined whether MRP3 is directly involved in the efflux pathway for bile salts in enterocytes. We observed that transcriptional control by FTF was an underlying mechanism for the up-regulation of the MRP3 gene in enterocytes by bile salts. In our present study, the luciferase activity driven by p-520, p-311, and p-229 was increased about 3-fold over the basal level when treated with 100 M of CDCA for 12 h, but the luciferase activity driven by p-138 was not changed, and the alteration of MRP3 promoter activity was comparable with induction of cellular MRP3 mRNA levels. These findings suggested that putative bile saltresponsive elements existed in the region between Ϫ229 and Ϫ138 (Fig. 3) . This region contains two FTF-like elements (Ϫ222/Ϫ218 and Ϫ199/Ϫ195), suggesting the close involvement of FTF in bile salt-induced up-regulation of the MRP3 gene in enterocytes.
FTF, a member of the Ftz-F1 family of orphan receptors, is expressed in the liver, pancreas, and gut, and it plays a role in hepatocyte bile salt synthesis. Feedback repression by bile salts of the CYP7A1 gene is mediated through interaction of FTF with its heterodimeric partner, the small heterodimer partner, induced by bile salt receptor FXR (10, 43, 44) . Furthermore, FTF appears to be essential for both expression and bile acid-mediated regulation of sterol 12␣-hydroxylase (9, 45).
Taking into consideration these results together, FTF appears to play an important role in the maintenance of bile acids and cholesterol homeostasis.
Several series of promoter constructs with a specific mutation in the consensus sequence of FTF showed no increase of the basal transcriptional activity by CDCA (Fig. 4B) . Both FTF-like elements seem likely to have a regulatory role in MRP3 expression in response to CDCA. These mutations of FTF-like elements did not affect the basal transcriptional activity (Fig. 4B) . In contrast, FTF appears to play a key role in the basal gene expression of both CYP7A1 and 12␣-hydroxylase (9, 45) . The regulatory involvement of FTF in MRP3 gene expression might be different from CYP7A1 and 12␣-hydroxylase gene expression. One could argue if any other factor might have a regulatory role in the basal expression of MRP3 gene. Our previous study indicated that the liver-abundant transcription factor C/EBP␤ at Ϫ356/Ϫ343 is required for the expression of another MRP family member, MRP2, in hepatocytes (41) . The MRP3 promoter also contains C/EBP␤ at Ϫ820/ Ϫ520 and C/EBP␣ at Ϫ520/Ϫ461 (Fig. 2) . However, deletion constructs of these sequences at Ϫ820/Ϫ520 and at Ϫ520/Ϫ461 showed significant promoter activity in enterocytes (Fig. 2) . The MRP3 gene is abundantly expressed in colon, small intestine, and liver in human (23) , but C/EBP␣ and C/EBP␤ might not be responsible for expression of the MRP3 gene in human colon cells.
Treatment with oxysterol, ligands of LXR, in fibroblasts or macrophages dramatically enhanced expression of the putative cholesterol/phospholipid ABC transporter ABCA1 through an oxysterol receptor, LXR (46) . A relevant study by Repa et al. (47) has also demonstrated that both LXR and FXR are the retinoid X receptor heterodimeric partners that mediate expression of ABCA1 and CYP7A1 genes, resulting in regulation of cholesterol homeostasis. Although the LXR motif exists at Ϫ311/Ϫ229 on the human MRP3 promoter, our present study showed that the bile salt-responsive element was Ϫ229/Ϫ138. Moreover, MRP3 promoter sequence does not contain the motifs corresponding to FXR and retinoid X receptor, suggesting the existence of pleiotropic regulatory mechanisms for expres- In EMSA, a specific protein-DNA binding activity was observed when treated with CDCA (Fig. 5B) . This protein-DNA binding activity was abolished when anti-FTF antibody was exogenously added, suggesting that the binding protein is in fact FTF (Fig. 6 ). Binding of the nuclear factor (FTF) to the oligonucleotide FTF binding sites was almost completely blocked by the unlabeled oligonucleotides and also by oligonucleotide containing the internal mutation of one of the two FTF sites (Fig. 5B) . By contrast, there appeared to be no competition resulting from the presence of the oligonucleotides containing mutation in both FTF sites. It appears likely that FTF binds to the two FTF sites on the MRP3 promoter and also that the FTF binding to both FTF sites is requisite for bile salt-induced MRP3 promoter activation.
The expression levels of FTF mRNA as well as MRP3 mRNA were markedly increased by CDCA (Fig. 7) . Overexpression of FTF enhanced MRP3 promoter activity but not when mutations were introduced in one or two FTF-like elements in the MRP3 promoter (Fig. 8) . These results suggested that bile salts might up-regulate the MRP3 gene through transcriptional control by altering the expression levels of FTF and also by interacting with as yet unidentified co-factors. Since bile acids do not act as ligand of FTF (45) , another factor mediating bile acid-dependent induction might be required. Further study is needed to know whether any other factor could also be responsible for bile acid-induced regulation in addition to FTF.
Bile salts often exert negative feedback regulation on their own synthesis in hepatocytes and interruption of the enterohepatic circulation enhanced cholesterol and bile acid synthesis, suggesting that a similar molecular basis of interaction of FTF and its two sites is responsible for bile acid-induced regulation of cholesterol bile acid biosynthesis and bile acid efflux transporter, MRP3. A recent study reported that FTF was induced by bile acid-activated FXR in hepatocytes (48) and might play its critical role in bile salt-induced alteration of relevant gene expression. FTF gene in enterocytes thus appears to be regulated in a way similar to the event in hepatocytes.
In conclusion, bile acid enhanced the expression of an ABC transporter, MRP3, which is known to efflux bile acids in human colon cells. This up-regulation of MRP3 by bile acid was mediated through binding of FTF to its binding sites on the MRP3 promoter. The results of these recent studies indicate that during enterohepatic circulation of bile salts, the transcription factor FTF may play a key role not only in bile acid biosynthesis in the liver but also in expression of MRP3 in the gut in response to bile acids (Fig. 9) . We suspect that the ABC transporter, MRP3, might also be involved in cholesterol/bile acid homeostasis.
